MPM Bioimpact LLC Acquires Shares of 950,000 Replimune Group, Inc. (NASDAQ:REPL)

MPM Bioimpact LLC bought a new position in shares of Replimune Group, Inc. (NASDAQ:REPL) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 950,000 shares of the company’s stock, valued at approximately $11,504,000. Replimune Group comprises 1.6% of MPM Bioimpact LLC’s investment portfolio, making the stock its 29th biggest position.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. grew its stake in Replimune Group by 3.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company’s stock valued at $2,733,000 after acquiring an additional 8,074 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Replimune Group by 14.7% in the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock valued at $318,000 after acquiring an additional 3,374 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Replimune Group by 24.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock worth $198,000 after buying an additional 3,177 shares during the period. Rhumbline Advisers grew its position in Replimune Group by 8.3% in the 4th quarter. Rhumbline Advisers now owns 95,465 shares of the company’s stock valued at $1,156,000 after acquiring an additional 7,317 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its position in Replimune Group by 260.8% in the 4th quarter. New York State Common Retirement Fund now owns 43,204 shares of the company’s stock valued at $523,000 after buying an additional 31,231 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

REPL has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their price target on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. HC Wainwright raised their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, BMO Capital Markets lifted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Replimune Group has a consensus rating of “Buy” and an average price target of $19.43.

Replimune Group Stock Performance

REPL opened at $7.41 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The stock has a market capitalization of $570.68 million, a price-to-earnings ratio of -2.41 and a beta of 0.68. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company has a fifty day moving average of $9.27 and a 200 day moving average of $11.45.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.